{"efta_number": "EFTA00586577", "page_count": 25, "url": "https://epstein-data.com/EFTA00586577", "pdf_url": "https://epstein-data.com/pdf/EFTA00586577.pdf", "pages": [{"efta_number": "EFTA00586577", "page_number": 0, "text_content": "OH2 Laboratories \nRe-engineering Drug Discovery \nCompany Overview \nFebruary 2015 \nDavid Levy, Ph.D. \nGeneral Manager and Chairman \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586577\n", "char_count": 197}, {"efta_number": "EFTA00586577", "page_number": 1, "text_content": "Introductions: \nThe OH2 Laboratories Team \nBoard of Managers \nDavid Levy, Ph.D. \nChairman and General Manager, OH2 \nFounder, Digit Wireless, LLC \nFounder, TH, Inc \nDesign Engineer, Apple \nMarc Rioult, Ph.D \nManaging Director, 3DMatrix \nSenior Licensing Officer, MIT TLO \nKevin Munnelly, Ph.D. \nPresident & CEO, Gen9 \nGM, Life Technologies, \nVP and GM, BioTrove \nSteve Yang, Ph.D. \nDirector, Sentilaia \nConsultant, McKinsey \nScientific Advisory Board \nShuguang, Zhang, Ph.D. \nLab Head, MIT \n170 publication \n36 patents and pending patents \nFounder, 3D Matrix \nMany awards \nRobert Langer, D.Sci. \nDavid H. Koch Institute Professor, MIT \n1,250 Publications \n1,050 patents \nMany awards \nMany, many Companies \nAlex Rich, M.D. \nProfessor of Biophysics, MIT \n550 Publications \nMany awards \nDavid Jin, M.D. \nPracticing Oncologist and Researcher \n2012 Top Chief Medical Officer in America \n2014 Leading Physicians in the World \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586578\n", "char_count": 985}, {"efta_number": "EFTA00586577", "page_number": 2, "text_content": "Significance of Our Work \nAbout 50% of medications function by GCPR signaling. \n99% of them were \"lucky\": They worked prior to \nscience understanding GPCRs. \nImagine if we could now target-design medications to \nsignal through specific GPCR receptors... \nOFI2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586579\n", "char_count": 322}, {"efta_number": "EFTA00586577", "page_number": 3, "text_content": "What We Do \nWe produce GPCRQTY, mAbc1TY, and ReceptorcITY : \nsynthetic materials created with our patented algorithms \nto target-design stable water-soluble variants of any \ndesired protein, especially membrane proteins, while \nmaintaining the functionality of the original. \nThe result is a foundational technology: \na fundamental tool that opens many doors. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586580\n", "char_count": 427}, {"efta_number": "EFTA00586577", "page_number": 4, "text_content": "Monetization \nThe ability to produce stable water-soluble versions of proteins that are \nnaturally insoluble brings value to several areas: \n• Drug Discovery \n• Research Tools \n• Diagnostics \n• mAB-Similar Products \n• Autoimmune/Allergy Therapy \n• Viral Therapeutics \n• Molecular Sensors \nOH2 is a holding company, ultimately intending to form subsidiaries to monetize each. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586581\n", "char_count": 442}, {"efta_number": "EFTA00586577", "page_number": 5, "text_content": "Drug Discovery \n151P \nGPCRQTY provides a critical revitalization of drying \npharma pipelines: \n— Addresses compounds with poor solubility (over 40% of drugs) \noffering increased efficacy and faster, cheaper development. \n— Enables novel drug candidates for GPCR-mediated diseases: \nProstate cancer \n(GPR68/OGR1) \nCancer metastasis (CXCR4) \nLeukemia (P2Y8/P2 R Y8) \nBipolar disorder (GPRS 78) \nOsteoarthritis (GPR22) \nBreast Cancer (CXCR4) \nParkinson's (GPCR 37) \nAsthma (CCR3.CXCR2) \nOvarian Cancer (OGR1) \nAutism (GPCR 63) \nLung cancer (GPR87) \nAlzheimer's (GPR3) \nArteriosclerosis (GPRS 176) \nColon cancer (MASI ) \nDiabetes (GPCR 21) \n(Plus over 700 others and the list grows almost daily.) \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586582\n", "char_count": 760}, {"efta_number": "EFTA00586577", "page_number": 6, "text_content": "Research Tools \nProviding GPCRQTY, mAbc1TY, and ReceptorQTY products to \nresearch laboratories, enables others to explore the \nbenefits of water-soluble proteins. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586583\n", "char_count": 230}, {"efta_number": "EFTA00586577", "page_number": 7, "text_content": "Diagnostics \nGPCRQTY materials maintains ligand binding ability to \nspecific antigens/receptors is a low-cost and stable medium \nenabling a new class of novel, low-cost diagnostics. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586584\n", "char_count": 249}, {"efta_number": "EFTA00586577", "page_number": 8, "text_content": "mAB-Similar Products \nmAbQT't' offers new molecular therapeutics: \n— Target-designed to be similar to monoclonal antibodies, but \neasier to produce. \n— Engineered to reduce mAb aggregation and increase long-\nterm storage. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586585\n", "char_count": 289}, {"efta_number": "EFTA00586577", "page_number": 9, "text_content": "Autoimmune/Allergy Therapy \nGPCRQTY can be used as a decoy therapy (similar to \nEnbrel/Etanercept). \nThis approach can theoretically be used for any disease or \ncondition associated with GPCR signaling. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586586\n", "char_count": 270}, {"efta_number": "EFTA00586577", "page_number": 10, "text_content": "Viral Therapeutics \nReceptorsQTY can be use to trap viruses including: HIV, \nEbola, Marburg & Lassa - for rapid reduction of viral loads. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586587\n", "char_count": 205}, {"efta_number": "EFTA00586577", "page_number": 11, "text_content": "Molecular Sensors \nDue to their stability, low-cost and high degree of molecular \nselectivity, Receptorsc/TY can be used to create ultra-\nsensitive bionic detectors. (e.g. a chip-based bionic nose.) \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586588\n", "char_count": 266}, {"efta_number": "EFTA00586577", "page_number": 12, "text_content": "The Science -\nUsing CXCR4 as an example \nThe following 7 slides explains how we can produce CXCR4QTY , \na functional soluble CXCR4 variant. \n• Re-Coding CXCR4 \n• Comparing Structures \n• Comparing Solubility \n• Thermal Stability \n• Circular dichroism Spectra \n• Natural SDF1 ligand Binding \n• X-Ray Diffraction \nThe variant structure was target-designed, not by trial and error. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586589\n", "char_count": 445}, {"efta_number": "EFTA00586577", "page_number": 13, "text_content": "Coding CXCR4QTY from CXCR4 \nTMHMM posteror probabilities for WI \n1.2 \n7 distinctive \nTrans membrane \nhelices \n0 Trans membrane \nhelices! \nI \n0.8 \n0.6 \n0.4 \n0.2 \n0 \n1.2 \n0.8 \n0.6 \n0.4 \n0.2 \n0 \n50 \n100 \ntransmembrane \n150 \n200 \ninside \nTMHMM posterior probabilities for MT \n250 \n300 \n960 \noutside \n50 \n100 \n160 \n200 \n250 \n900 \n960 \ntransmembrane \nkakis — \noutside \n— \nEFTA00586590\n", "char_count": 379}, {"efta_number": "EFTA00586577", "page_number": 14, "text_content": "Comparing Structures -\nNatural & CCR4 Variant, Superimposed \nThe two structures are nearly identical. \nView #1 \nView #2 \nLaboratories, LLC \nConfidential and Proprietary \nEFTA00586591\n", "char_count": 183}, {"efta_number": "EFTA00586577", "page_number": 15, "text_content": "Natural CXCR4 \nHydrophobic Regions \nComparing H2O Solubility \nDesigned Variant CXCR4QTY \nHydrophobic Regions \nOd: Loboratcrie, LLC \nConfidential and Proprietary \nEFTA00586592\n", "char_count": 175}, {"efta_number": "EFTA00586577", "page_number": 16, "text_content": "Native CXCR4 and CXCR4 variant \"1 \nThe CD spectra \nMolecular models \nCD spectrum of natural CXCR4 and water-soluble CXCR4 QTY \nA \nNative \nprotein \n8 \n6 \nB \nQTY \nvariant \n4 0 \nI 0\n4 \n3 \n0a) \n2 \n• \n2 \n0 \n£ \n1 \n0 \n0 \n0 \n• \n0 \n-1 \n0 \nO \n6 15499°)\n-2 \n• \n• \nO \n/ \n-4 \n-2 \n• \n-3 \nWI \n-6 \n\\pow/ \n-8 \n195 \n205 \n215 \n225 \n235 \n245 \nWavelength (nm) \n195 \n205 \n215 \n225 \n235 \n245 \nWavelength (nm) \nRed, Native CXCR4 \nBlue, CXCR4QTY variant \nThe structures are \nnearly \nThe same. \nEFTA00586593\n", "char_count": 482}, {"efta_number": "EFTA00586577", "page_number": 17, "text_content": "Thermal Stability of \nWater-soluble CXCR4QTY, Tm 67°., \nA \n10 \n0• \nI \n▪ -lo-\not \n- \n-30 - \n5 \n15 \n25 \n35 \n45 \n55 \n65 \n-10-\n-127\n-14-\n-16-\n-le• \nN -20-\nN \nZ• -22- \n-24- \n-32-\nB \n200 \n210 \n220 \n230 \n240 \n250 \n260 \n0 \n20 \n40 \n60 \nWavelength \nTemperature (C) \nea \n100 \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586594\n", "char_count": 331}, {"efta_number": "EFTA00586577", "page_number": 18, "text_content": "Ligand-binding of CXCR4QTY \nwith its natural ligand CXCL12 \nELISA-style binding assay \nCXCR4 QTY-CXCL12 \n1,2 \n1 \n■ • \nMEN \n0,8 \n•\n■ \n• \n0,6 \n• \n0,4 \n•\n0 \n0,2 \n■ \n0 \n■• \n■ \n<0 \nCP \nN'N\nQr \nN<,P \n• \nb \n(0. \n4 ). \n,ek s\nLog CXCL12 [nM] \nThe natural SDF1a ligand-binding assay. The SDF1a binds to the native CXCR4 - 1.00nM. \nThe SDF1a binds to the designed code made CXCR4 variant - 80nM. \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586595\n", "char_count": 452}, {"efta_number": "EFTA00586577", "page_number": 19, "text_content": "X-ray diffraction of crystal of \nwater-soluble CXCR4QTY \nOHz Laboratories, LLC \nConfidential and Proprietary \nEFTA00586596\n", "char_count": 123}, {"efta_number": "EFTA00586577", "page_number": 20, "text_content": "First Patent Issued \n111111111111111111111111 \n(12) United States Patent \nZhang et al. \n(lo) Patent No.: \nUS 8,637,452 82 \n(45) Date of Patent: \nJan. 28, 2014 \n(54) WAFER St/1.1;111.E MEMBRANE PROTEINS \nAND METHODS FOR THE PREPARATION \nAND USE THEREOF \n2011/0028700 Al \n212011 Heal \n2011/0046351 Al \n2/2011 Weir et al. \n201110112037 Al \n5/2011 Warne et al. \n2012/0165507 Al \n6/2012 Jazayeri-Dezfuly et al. \n(75) Inventors: Shugnang Zhang, Lexington, MA (US); \nFOREIGN PATENT DOCUMENTS \nAlexander Rich, Cambridge, MA (US); \nKarol na Corin. Irvine, CA (US); Lotto \nEP \n1270724 A2 • \n2/2003  \n Cl2N 15/12 \nT.1Cgler. Linkoping (SE) \nWO \nWO 2007/089899 \n• \n2/2007  \n C07K 14/705 \nWO \n2008/114020 A2 \n9/2008 \n(73) Assignee: Massachusetts Institute of Technology, \nCambridge. MA (US) \nWO \nWO \nWO \n2011/095625 AI \n8/2011 \n20121066330 Al \n5/2012 \n2012/098413 Al \n7/2012 \nWO \n2012/120315 A2 \n9/2012 \nZhang, S and Tao Fei, Design Code for Design code of detergent-free \nG protein-coupled receptors substituting hydrophobic amino acids \nusing non-ionic amino acids and uses thereof. MIT case No. 16938X \n(To be filed in 2014) \n0H2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586597\n", "char_count": 1181}, {"efta_number": "EFTA00586577", "page_number": 21, "text_content": "Shuguang Zhang, Ph.D. \nInventor of self-assembling \nPeptide nanofiber scaffolds \n. \n4\n14A\nr ta\n2 ,  A •ingle papInfr \n.16 amino adthi \nI lb.uvoil, µ Wok III..,-\n 1,1111,nn \nIM.,IT.hl\nAcademic Biography \n• \nInstitute: Center for Bits and Atoms, MIT \n• \nAlma mater: PhD, Biochemistry & Molecular Biology, Department of \nBiological Sciences, University of California, B.S., Sichuan University, \nChina. \n• \nAward: Winner of R&D100 award for peptide matrix, Wilhelm Exner \nMedal of Austria. Fellow of US National Academy of Inventors, Fellow of \nAmerican Institute of Medical & Biological Engineering. \n• \nForeign Member of the Austrian Academy of Sciences in Vienna, Fellow \nof the American Institute of Medical & Biological Engineering, Honorary \nProfessor of China University of Petroleum and Sichuan & Shanghai \nJiaotong University. \n• \n16 issued patents and 20 pending patent applications. \n• \nPublished over 170 scientific papers. \nBusiness Biography \n• \nCo-founder of biotech startups 3-D Matrix., Ltd. (7777:JP), IPO in Japan \nin 2011 October on JASDAQ (current valuation \n• \n- $800 millions September 2014). \n• \nCo-Founder and Board member of Molecular Frontiers Foundation, a \nglobal organization with objective to early identify breakthroughs in \nscience and to stimulate young people's interests in science. \nOH) Laboratories, LLC \nConfidential and Proprietary \nEFTA00586598\n", "char_count": 1382}, {"efta_number": "EFTA00586577", "page_number": 22, "text_content": "Robert S. Langer, Sc.D. \nFather of controlled \ndrug release & tissue \nengineering \nAcademic Biography \n■ \nInstitutions: David H. Koch Institute Professor at the Massachusetts \nInstitute of Technology \n■ \nAlma mater: Cornell University (Sc.D.), Massachusetts Institute of \nTechnology (B.C.) \n• \nAwards: Priestley Medal, US National Medal of Science, 10th Annual Heinz \nAward in the category of Technology, Economy and Employment, Charles \nStark Draper Prize, Lemelson-MIT Prize, Albany Medical Center Prize in \nMedicine and Biomedical Research, Millennium Technology Prize. \n■ \nMember of US National Academy of Sciences, of Engineering and of \nInstitute of Medicine. \nK \nConsidered a pioneer of many new technologies, including transdermal \ndelivery systems, which allow the administration of drugs or extraction of \nanalytes from the body through the skin without needles or other invasive \nmethods, and the creation of engineered blood vessels and vascularized \nengineered muscle tissue. \nK \nMaintained a research laboratory at MIT, which is the largest biomedical \nengineering lab in the world, maintaining about $10 million in annual \ngrants and over 100 researchers. \nK \nHeld more than 1020 granted or pending patents. \nK \nAuthored more than 1,100 scientific papers. \nBusiness Biography \nK \nParticipated in the founding of multiple technology companies. \nK \nCo-Founders for over 25 biotechnology companies. \nK \nBoard members, scientific advisors and consultants for -100 entities. \nK \nGenerated over $100 billion biotech business worIgivyyMarmyy. \nConfidential and Proprietary \nEFTA00586599\n", "char_count": 1595}, {"efta_number": "EFTA00586577", "page_number": 23, "text_content": "Alexander Rich, M.D. \nDiscover of structures of \ncollagen, RNA double \nhelix, tRNA, Z-DNA \nAcademic Biography \nK \nInstitutions: The William Thompson Sedgwick Professor of Biophysics at MIT since 1958. \nK \nAlma mater: A.B. Harvard University and an M.D. from Harvard Medical School. \nK \nAwards: US National Medal of Science, MIT James Killian Award, Linus Pauling Medal, Lewis \nRosenstiel Award, William Procter Prize, Lomonosov Medal. Passano Award, Bower Award and the \nWelch Award. \nK \nMember of US National Academy of Sciences, Institute of Medicine and Philosophical Society. \nForeign member of French Academy of Sciences, Russian Academy of Sciences and Pontifical \nAcademy of Sciences. \nK \n5 Honorary Ph.D. from ETH-Zurich, Weizmann Institute of Science. Freie University-Berlin, Federal \nUniversity of Rio de Janerio and Sichuan University, China. \nK \nDiscovered nuclei acid hybridization. RNA double helix, DNA-RNA hybrid double helix, molecular \nstructure of collagen, of tRNA, of DNA-anticancer drug complexes and polyribosomes. \nK \nDetermined the molecular structure of left-handed double helix Z-DNA. This was the first single \ncrystal structure of any form of DNA, published on the cover of Nature in Dec 1979. After 26 years \nof attempts, Rich and colleagues finally determined molecular structure of the junction of B-DNA \nand Z-DNA. Their results were again published on the cover in Nature in Oct 2005. \n■ \nEditorial board of more than 20 journals including Science, PNAS, J.Mol. Biol., EMBO J.. RNA and \nGenomics. \nBusiness Biography \n■ \nCo-Founder and the Co-Chairman of the Board of Directors of Repligen Corporation (NASDAQ: \nRGEN), a biopharmaceutical company since 1981. \n■ \nCo-Founder and Board of Directors , Alkermes , Inc. (NASDAQ: ALKS) and has been its director \nsince 1987. \n■ \nCo-Founder 3DMatrix, Inc., Tokyo, Japan, 2002; Co-Founder and Board of Directors for Profectus \nBioSciences, Inc. 2004; Co-Founder, Beaver Biosciences, Guangzhou, China, 2009. \n■ \nScientific Advisor for 11 biotech companies. \nEFTA00586600\n", "char_count": 2047}, {"efta_number": "EFTA00586577", "page_number": 24, "text_content": "Next Steps/Raise \nOur next step is to demonstrate our process on 14 GPCRs \nsimultaneously, as a final proof of concept. This work will take \n4 months. At that milestone, we will publish scientific papers, \nraise money to form our first spin out company. \nCurrent raise: \n$800K in convertible notes at a 30% discount to Series A \nOH2 Laboratories, LLC \nConfidential and Proprietary \nEFTA00586601\n", "char_count": 395}]}